№ lp_2_3_59971
File format: docx
Character count: 28582
File size: 3039 KB
This educational resource outlines a sequence of learning activities for Year 12 biology students, focusing on the SARS-CoV-2 virus, RNA, mutations, and the role of vaccines in disease prevention.
Year:
2020
Region / City:
New South Wales, Australia
Topic:
Biology, SARS-CoV-2, RNA, Vaccination, Infectious Diseases
Document Type:
Educational Resource
Organization / Institution:
New South Wales Education Standards Authority (NESA)
Author:
Not specified
Target Audience:
Year 12 students
Period of Validity:
2020 and onwards
Approval Date:
2017
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2020
Region / city:
Global
Theme:
COVID-19 Pandemic, Health Risk Assessment
Document type:
Report
Organization:
Centers for Disease Control and Prevention (CDC), World Health Organization (WHO)
Author:
Centers for Disease Control and Prevention (CDC)
Target audience:
Public health officials, healthcare providers, researchers
Validity period:
Ongoing
Approval date:
October 19, 2020
Date of changes:
Ongoing
Year:
2021
Region / city:
United States
Topic:
COVID-19, occupational health, risk assessment
Document type:
Report
Organization / institution:
CSTE Occupational Health Subcommittee
Author:
CSTE Occupational Health Subcommittee, Work Group on Essential Workers - Exposure Measures Team
Target audience:
Epidemiologists, policymakers, occupational health experts
Effective period:
From August 18, 2021
Approval date:
August 18, 2021
Date of changes:
August 18, 2021
Year:
2020
Region:
Guangdong Province, China
Topic:
Genomic epidemiology of SARS-CoV-2
Document type:
Supplementary information to a scientific research article
Associated article:
Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China
Authors:
Jing Lu; Louis du Plessis; Zhe Liu; Verity Hill; Min Kang; Huifang Lin; Jiufeng Sun; Sarah François; Moritz U G Kraemer; Nuno R Faria; John T McCrone; Jingju Peng; Qianlin Xiong; Runyu Yuan; Lilian Zeng; Pingping Zhou; Chuming Liang; Lina Yi; Jun Liu; Jianpeng Xiao; Jianxiong Hu; Tao Liu; Wenjun Ma; Wei Li; Juan Su; Huanying Zheng; Bo Peng; Shisong Fang; Wenzhe Su; Kuibiao Li; Ruilin Sun; Ru Bai; Xi Tang; Minfeng Liang; Josh Quick; Tie Song; Andrew Rambaut; Nick Loman; Jayna Raghwani; Oliver G Pybus; Changwen Ke
Affiliated institutions:
Guangdong Provincial Center for Disease Control and Prevention; University of Oxford; University of Edinburgh; Shenzhen Center for Disease Control and Prevention; Guangzhou Center for Disease Control and Prevention; Guangdong Provincial Second People’s Hospital; Foshan First People’s Hospital; University of Birmingham
Data coverage period:
Up to 19 March 2020
Number of reported genomes:
53 newly reported SARS-CoV-2 genomes
Total cases referenced:
1388 laboratory-confirmed COVID-19 cases
Figures:
S1–S4
Tables:
S1–S2
Data sources:
RT-PCR testing; whole-genome sequencing; GISAID database
Geographic scope of comparative data:
Guangdong; Hubei; USA (California, Wisconsin); Japan; Singapore; Jiangsu; Fujian; India; Vietnam
Year:
2021
Region / city:
Various locations in the United States
Topic:
COVID-19 Treatment
Document type:
Clinical Trial Report
Institution:
Regeneron Pharmaceuticals, NIAID/CoVPN
Author:
Multiple investigators and research teams
Target audience:
Healthcare professionals, researchers, clinical trial coordinators
Period of validity:
Study conducted during 2020-2021
Approval date:
Not specified
Date of changes:
Not specified
Document Type:
Supplementary data appendix
Subject:
Development and validation of a rapid viability RT-PCR (RV-RT-PCR) method for detection of infectious SARS-CoV-2
Pathogen:
SARS-CoV-2
Experimental Model:
Vero E6 cells
Institutions:
U.S. Environmental Protection Agency, Office of Research and Development; Lawrence Livermore National Laboratory
Authors:
Sanjiv R. Shah; Staci R. Kane; Maher Elsheikh; Teneile M. Alfaro
Geographic Location:
Washington, District of Columbia, USA; Livermore, California, USA
Data Type:
RT-PCR cycle threshold (CT) measurements; plaque forming units (PFU); TCID50 values; recovery efficiency data
Infection Conditions:
1-hour and 2-hour infection periods with post-infection incubation at T0, T12, and T24
Sample Type:
SARS-CoV-2-infected cell cultures and swab swatches
Analytical Replicates:
Triplicate RT-PCR analyses with pooled standard deviations
Tables Included:
Table S1; Table S2; Table S3; Table S4
Year:
2022
Region / City:
N/A
Subject:
Molecular interaction studies
Document Type:
Supplementary data
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Researchers in biochemistry, molecular biology, and virology
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2021
Study type:
Clinical research
Document type:
Supplementary materials
Authors:
Not specified
Institution:
Not specified
Target audience:
Researchers in oncology and virology
Tumor types:
Glioma, Meningioma, Pituitary adenoma, Craniopharyngioma, Ependymoma, Schwannoma, Haemangioblastoma, Chordoma, Brain metastases from breast, lung, kidney, colon cancer
Methods:
Immunohistochemistry, Immunofluorescence, Gene expression analysis, KEGG enrichment, GSEA
Patient information:
Age, Sex, Preexisting conditions, Preoperative treatment, SARS-CoV-2 PCR status
Figures included:
S1–S6
Tables included:
S1
Key markers analyzed:
ACE2, TMPRSS2, CD147, NRP1, IFN-γ, PD-1, FOXP3, CD8, CD4, C1q, C3, IgG, IgM, CD68, TTF1, MUC1
Year:
2026
Region / Institution:
Not specified
Topic:
Immunology, SARS-CoV-2, Vaccine Response
Document type:
Peer Review
Author:
Stefania P Bjarnarson
Target audience:
Researchers, Immunologists
Study period:
Up to 33 months post mRNA vaccination
Methods:
Analysis of bone marrow plasma cells, healthy adult donors, post-vaccination sampling
Key findings:
Limited presence of SARS-CoV-2-specific long-lived plasma cells in bone marrow after mRNA vaccination or hybrid immunity
Data source:
Bone marrow aspirates, hip joint replacement surgery samples
Limitations:
Small sample size, discrepancies in patient description, consideration of asymptomatic infections
Scientific relevance:
Provides evidence on the longevity of humoral immune response post-vaccination
Concise description:
Peer-reviewed evaluation of a study assessing the presence of SARS-CoV-2-specific long-lived plasma cells in the bone marrow following mRNA vaccination and hybrid immunity, highlighting methodology, key results, and points for revision.
Year:
2020
Region / city:
United States, multiple states
Theme:
SARS-CoV-2, Healthcare personnel, COVID-19
Document type:
Protocol
Organization / institution:
Centers for Disease Control and Prevention (CDC), Emerging Infections Program
Author:
CDC Division of Healthcare Quality Promotion
Target audience:
Healthcare personnel, public health professionals, researchers
Period of action:
2020
Date of approval:
July 17, 2020
Date of changes:
Not specified
Context description:
Protocol for tracking SARS-CoV-2 infections and assessing risks among healthcare personnel in the United States during the COVID-19 pandemic.
Year:
2020
Region / city:
United States
Topic:
Healthcare personnel, SARS-CoV-2, COVID-19
Document Type:
Protocol
Organization:
Centers for Disease Control and Prevention (CDC), Emerging Infections Program
Author:
Centers for Disease Control and Prevention (CDC)
Target Audience:
Healthcare personnel, public health officials, researchers
Period of Validity:
Ongoing
Approval Date:
April 22, 2020
Date of Changes:
Not specified
Year:
2026
Region / city:
Darmstadt, Germany
Topic:
RNA Aptamers, SELEX, Homooriodictyol
Document type:
Research article
Organization / institution:
TU Darmstadt
Author:
Janis Hoetzel, Cristina Bofill-Bosch, Andres W. Martinez, Martin M. Rudolph, Florian Groher, Beatrix Suess
Target audience:
Researchers, biochemists, molecular biologists
Date of approval:
2026
Date of changes:
2026
Note:
Contextual description
Year:
2021
Region / City:
Not specified
Topic:
RNA Extraction
Document Type:
Standard Operating Procedure (SOP)
Organization:
Not specified
Author:
Subash Kumar Rai
Target Audience:
Laboratory Personnel
Effective Date:
28 Oct 2021
Date of Approval:
28 Oct 2021
Date of Last Review:
Not specified
Period of Validity:
Indefinite
Date of Revision:
Not specified
Year:
2016
Region / city:
Sydney
Subject:
DNA/RNA extraction, laboratory safety
Document type:
Standard Operating Procedure
Organization:
The University of Sydney
Author:
Coleman, N.; Nikolic, A.
Target audience:
Laboratory personnel, researchers
Period of validity:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Year:
2015
Region / city:
Global
Topic:
RNA extraction, clinical samples, FTA cards
Document Type:
Protocol
Organization:
CDC, GMRLN, WHO
Author:
CDC
Target Audience:
Laboratory professionals
Period of validity:
N/A
Approval Date:
01/27/2015
Date of Changes:
N/A
Note:
Year
Topic:
Gene Editing
Document Type:
Cheat Sheet
Target Audience:
Educators, Researchers in Genetics
Year:
2023
Region / City:
Not specified
Topic:
DNA and RNA isolation protocols
Document Type:
Supplementary Data
Author:
Not specified
Target Audience:
Researchers in molecular biology and genomics
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2007-2008
Region / City:
Yucatan Peninsula, Mexico
Topic:
Virus discovery, Mosquitoes, Metagenomics
Document type:
Research Article
Organization / Institution:
Iowa State University, University of Cambridge, Universidad Autónoma de Yucatán
Author:
Jermilia Charles, Chandra S. Tangudu, Stefanie L. Hurt, Charlotte Tumescheit, Andrew E. Firth, Julian E. Garcia-Rejon, Carlos Machain-Williams, Bradley J. Blitvich
Target Audience:
Researchers, Academics, Microbiologists
Period of Validity:
Not applicable
Approval Date:
Not mentioned
Date of Changes:
Not applicable
Year:
2023
Region / City:
Ohio, USA
Topic:
Nanotechnology, RNA Nanoparticles, Cancer Targeting
Document Type:
Research Article
Organization / Institution:
The Ohio State University, Wexner Medical Center
Author:
Hongzhi Wang, Chiran Ghimire, Hui Li, Mario Vieweger, Congcong Xu, Peixuan Guo
Target Audience:
Researchers, Scientists, Medical Professionals
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Context